Accès gratuit
Numéro
Med Sci (Paris)
Volume 20, Numéro 12, Décembre 2004
Page(s) 1100 - 1103
Section M/S revues
DOI https://doi.org/10.1051/medsci/200420121100
Publié en ligne 15 décembre 2004
  1. Levey AS, Beto JA, Coronado BE, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease. What do we know ? What do we need to learn ? Where do we go from here ? National kidney foundation task force on cardiovascular disease. Am J Kidney Dis 1998; 32 : 853–906. [Google Scholar]
  2. Parfrey P, Foley R. The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 1999; 10 : 1606–15. [Google Scholar]
  3. Uhlig K, Levey A, Sarnak M. Traditional cardiac risk factors in individuals with chronic kidney disease. Semin Dial 2003; 16 : 118–27. [Google Scholar]
  4. Longenecker J, Coresh J, Powe N, et al. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population : the CHOICE study. J Am Soc Nephrol 2002; 13 : 1918–27. [Google Scholar]
  5. US department of health and human services. National center for health statistics, third national health and nutrition examination survey, 1988–1994. NHANES III. Hyattsville, MD : Centers for Disease Control and Prevention, 1994. [Google Scholar]
  6. Oparil S, Oberman A. Nontraditional cardiovascular risk factors. Am J Med Sci 1999; 317 : 193–207. [Google Scholar]
  7. Madore F. Uremia-related metabolic cardiac risk factors in chronic kidney disease. Semin Dial 2003; 16 : 148–56. [Google Scholar]
  8. Foley R, Parfrey P, Harnett J, et al. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 1996; 28 : 53–61. [Google Scholar]
  9. Ganesh SK, Stack AG, Levin NW, et al. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001; 12 : 2131–8. [Google Scholar]
  10. Ross R. Atherosclerosis : an inflammatory disease. N Engl J Med 1999; 340 : 115–26. [Google Scholar]
  11. Ridker PM, Buring JE, Shih J, et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98 :731–3. [Google Scholar]
  12. Ridker PM, Henekens CH, Furing JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342 : 836–43. [Google Scholar]
  13. Anonymous. C-reactive protein and atherosclerosis in dialysis patients. Nephrol Dial Transpl 1998; 13 : 2710–1. [Google Scholar]
  14. Zimmermann J, Herrlinger S, Pruy A, et al. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55 : 648–58. [Google Scholar]
  15. Ridker P, Cushman M, Stampfer M, et al. Inflammation, aspirin, and risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336 : 973–9. [Google Scholar]
  16. Ridker P, Rifai N, Pfeffer M, et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The cholesterol and recurrent events (CARE) investigators. Circulation 1999; 100 : 230–5. [Google Scholar]
  17. Sies H. Oxidative stress : oxidants and antioxidants. Exp Physiol 1997; 82 :291–5. [Google Scholar]
  18. Kita T, Kume N, Minami M, et al. Role of oxidized LDL in atherosclerosis. Ann NY Acad Sci 2001; 947 : 199–205. [Google Scholar]
  19. Hasselwander O, Young IS. Oxidative stress in chronic renal failure. Free Radic Res 1998; 29 : 1–11. [Google Scholar]
  20. Boaz M, Matas Z, Biro A, et al. Serum malondialdehyde and prevalent cardiovascular disease in hemodialysis. Kidney Int 1999; 56 : 1078–83. [Google Scholar]
  21. Boaz M, Smetana S, Weinstein T, et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE) : randomised placebo-controlled trial. Lancet 2000; 356 : 1213–8. [Google Scholar]
  22. Moustapha A, Naso A, Nahlawi M, et al. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation 1998; 97 : 138–41. [Google Scholar]
  23. Bostom AG, Shemin D, Verhoef P, et al. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study. Arterioscler Thromb Vasc Biol 1997; 17 : 2554–8. [Google Scholar]
  24. Mallamaci F, Zoccali C, Tripepi G, et al. Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int 2002; 61 : 609–14. [Google Scholar]
  25. Jungers P, Massy ZA, Khoa TN, et al. Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients : a prospective study. Nephrol Dial Transpl 1997; 12 : 2597–602. [Google Scholar]
  26. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000; 102 : 1082–5. [Google Scholar]
  27. Ernst E, Resch K. Fribrinogen as a cardiovascular risk factor : a meta-analysis and review of the literature. Ann Intern Med 1993; 118 : 956–63. [Google Scholar]
  28. Han D, Haudenshild C, Hong M, et al. Evidence for a possible role of apoptosis in atherogenesis. Am J Pathol 1995; 147 : 267–77. [Google Scholar]
  29. Troyanov S, Hebert MJ, Masse M, et al. Soluble Fas : a novel predictor of atherosclerosis in dialysis patients. Am J Kidney Dis 2003; 41 : 1043–51. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.